The development of platforms for the controlled release of therapeutic molecules remains a crucial research focus, as controlled release reduces the frequency of administration, minimizes side effects and improves compliance. However, biological conditions and diseases with a progression that exhibits strong temporal dependence, or those that can result in the evolution of tolerance to the therapeutic during continuous exposure, require the development of sophisticated release systems tailored to the needs to the individual and the disease. Thus, there has been emphasis on the development of platforms with remotely controlled release mechanisms. Specifically, magnetically triggered release utilizes magnetic nanoparticles as the remote control modality. Many reviews discuss the magnetically triggered release of small molecule drugs, however, the release of biomacromolecules has not been reviewed. This review examines the limited work on the magnetically triggered release of biomacromolecules and the challenges associated with their delivery. Important material parameters that have been used in this pursuit are discussed.

中文翻译：

---

磁性触发生物制剂的释放

治疗性分子控释平台的开发仍然是关键的研究重点，因为控释可减少给药频率，最大程度减少副作用并提高依从性。然而，具有表现出强烈的时间依赖性的进展的生物状况和疾病，或者在连续暴露期间可能导致对治疗剂的耐受性发展的那些生物学状况和疾病，需要开发适合于个体和疾病需求的复杂的释放系统。因此，一直侧重于具有远程控制释放机制的平台的开发。具体而言，磁性触发释放利用磁性纳米颗粒作为远程控制方式。许多评论都讨论了磁性触发的小分子药物的释放，但是，尚未审查生物大分子的释放。这项审查审查了生物大分子的电磁触发释放方面的有限工作以及与它们的传递有关的挑战。讨论了用于此追求的重要材料参数。